Pharmacologic hemodynamic support in massive pulmonary embolism

Chest

Volumn 111, Issue 1, 1997, Pages 218-224

  Layish, Daniel T ^a   Tapson, Victor F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

inotropes; pulmonary embolism; vasopressors

Indexed keywords

ACETYLCHOLINE; ADRENALIN; AMRINONE; DOBUTAMINE; DOPAMINE; FIBRINOLYTIC AGENT; GLYCERYL TRINITRATE; HEPARIN; HYDRALAZINE; ISOPRENALINE; MILRINONE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; PROSTAGLANDIN E1; UROKINASE; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; BALLOON DILATATION; CORONARY ARTERY BLOOD FLOW; DOG; DRUG MECHANISM; DRUG MIXTURE; EMBOLECTOMY; HEART HEMODYNAMICS; HEART OUTPUT; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE PRESSURE; HYPOTENSION; HYPOXIC LUNG VASOCONSTRICTION; LUNG EMBOLISM; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW;

EID: 0031037603     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.111.1.218     Document Type: Review

References (55)

1. Dalen JE, Alpert JS. Natural history of pulmonary embolism. Prog Cardiovasc Dis 1975; 17:259-70
2. Alpert JS, Smith R, Carlson CJ, et al. Mortality in patients treated for pulmonary embolism. JAMA 1976; 236:1477-80
3. Duranceau A, Jamieson GG, Jones HH, et al. An experimental model of pulmonary embolism. J Surg Res 1979; 26:33-44
4. Johnson A, Malik AB. Pulmonary edema after glass bead microembolization: protective effect of grannlocytopenia. J Appl Physiol 1982; 52:155-61
5. Malik AB, Zee HVD. Lung vascular permeability following progressive pulmonary embolization. J Appl Physiol 1978; 45:590-97
6. Deleroix M, Melot C, Yachiery JL. et al. Effects of embolus size on hemodynamics and gas exchange in canine embolic pulmonary hypertension. J Appl Physiol 1990; 69:2254-61
7. Malik AB, Zee HVD. Time course of pulmonary vascular response to microembolization. J Appl Physiol 1977; 43:51-8
8. Aviado DM, Cho YW. Pulmonary pharmacologies In: Gordon BL, Carleton RA, Faber LP, eds. Clinical cardiopulmonary physiology. 3rd ed. New York: Grune & Stratton, 1969; 718-19
9. McIntyre KM, Sasahara AA. Hemodynamic and ventricular responses to pulmonary embolism. Prog Cardiovasc Dis 1974; 17:175-90
10. Vaage J, Piper PJ. The release of prostaglandin-like substances during platelet aggregation and pulmonary microembolism. Acta Physiol Scand 1975; 94:8-13
11. Levy SE. Shapiro BJ, Simmons DH. Pulmonary hemodynamics after autologons in vivo pulmonary thromboembolism. J Appl Physiol 1969; 27:53-60
12. Ducas J, Prewitt RM. Pathophysiology and therapy of right ventricular dysfunction due to pulmonary embolism. Cardiovasc Clin 1987; 17:191-202
13. Vlahakes GJ, Turley K, Hoffman J. The pathophysiology of failure in acute right ventricular hypertension: hemodynamic and biochemical correlations. Circulation 1981; 63:87-95
14. Bemis CE, Serur JR, Borkenhagen D, et al. Influence of right ventricular filling pressure on left ventricular pressure and dimension. Circ Res 1974; 34:498-504
15. Manier G, Castaing Y, Guenard H. Determinants of hypoxemia during the acute phase of pulmonary embolism in humans. Am Rev Respir Dis 1985; 132:332-38
16. Weber KT, Janicki JS, Shroff SG. et al. The right ventricle: physiologic and pathophysiologic considerations. Crit Care Med 1983; 11:323-28
17. Manier G, Castaing Y. Influence of cardiac output on oxygen exchange in acute pulmonary embolism. Am Rev Respir Dis 1992; 145:130-36
18. Ducas J, Stitz M, Gu S, et al. Pulmonary vascular pressureflow characteristics: effects of dopamine before and after pulmonary embolism. Am Rev Respir Dis 1992; 146:307-12
19. Ducas J, Duval D, Dasilva H, et al. Treatment of canine pulmonary hypertension: effects of norepinephrine and isoproterenol on pulmonary vascular pressure-flow characteristics. Circulation 1987; 75:235-42
20. Molloy DW, Lee KY, Girling L, et al. Treatment of shock in a canine model of pulmonary embolism. Am Rev Respir Dis 1984; 130:870-74
21. Ghiguone M, Girling L, Prewitt RM, Volume expansion versus norepinephrine in treatment of a low cardiac output complicating an acute increase in right ventricular afterload in dogs. Anesthesiology 1984; 60:132-35
22. Mathru M, Venus B, Smith R, et al. Treatment of low cardiac output complicating acute pulmonary hypertension in normovolemic goats. Crit Care Med 1986; 14:120-24
23. Rosenberg JC, Hussain R, Lenaghan R. Isoproterenol and norepinephrine therapy for pulmonary embolism shock. J Thorac Cardiovasc Surg 1971; 62:144-50
24. Imamoto T, Yamashita H. Onodera S. Treatment ot canine acute pulmonary embolic shock: effects of isoproterenol and norepiuephrine on hemodynamics and ventricular wall motion. Jpn Circ J 1990; 54:1246-57
25. Augle MR, Molloy DW, Penner B, et al. The cardiopulmonary and renal hemodynamic effects of norepinephrine in canine pulmonary embolism. Chest 1989; 95:1333-37
26. Ducas J, Girling L, Schick U, et al. Pulmonary vascular effects of hydralazine in a canine preparation of pulmonary thromboembolism. Circulation 1986; 73:1050-57
27. Molloy DW, Lee KY, Jones D, et al. Effects of noradrenaline and isoproterenol on cardiopulmonary function in a canine model of acute pulmonary hypertension. Chest 1985; 88: 432-35
28. McDonald IG, Hirsh J, Hale GS, et al. Isoproterenol in massive pulmonary embolism: haemodynamic and clinical effects. Med J Aust 1968; 2:201-04
29. Hirsch LJ, Booney MW, Wat SS, et al. Norepinephrine and phenylephrine effects on right ventricular function in experimental caniue pulmonary embolism. Chest 1991; 100:796-801
30. Ducas J, Deutscher R, Prewitt RM. Inotropic vs vasopressor agents in acute right ventricular failure [abstract]. Am Rev Respir Dis 1985; 131:A149
31. Boulain T, Lanotte R, Legras A. et al. Efficacy of epinephrinc therapy in shock complicating pulmonary embolism. Chest 1993; 104:300-02
32. Jardin F, Genevray B, Brun-Ney D, et al. Dobutamine: a hemodynamic evaluation in pulmonary embolism shock. Crit Care Med 1985; 13:1009-12
33. Hayes MA, Timmius AC, Yan EHS, et al. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994; 330:1717-22
34. Gattinoni L, Brazzi L, Pelosi P, et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. N Engl J Med 1995; 333:1025-32
35. Wolfe MW, Saad RM, Spence TH. Hemodynamic effects of amrinone in a caniue model of massive pulmonary embolism. Chest 1992; 102:274-78
36. Prielipp RC, Butterworth JF IV, Zaloga GP. et al. Effects of amrinone on cardiac index, venous oxygen saturation and venous admixture in patients recovering from cardiac surgery. Chest 1991; 99:820-25
37. Hill NS, Rounds S, Amrinone dilates pulmonary vessels and blunts hypoxic vasoconstriction in isolated rat lungs. Proc Soc Exp Biol Med 1983; 173:205-12
38. Spence TH, Newton WD, Pulmonary embolism: improvement in hemodynamic function with amrinone therapy. South Med J 1989; 82:1267-68
39. Tanaka H, Tajimi K, Matsumoto A, et al. Vasodilatory effects of milrinone on pulmonary vasculature in dogs with pulmonary hypertension due to Pulmonary embolism: a Comparison with those of dopamine and dobutamine. Clin Exp Pharmacol Physiol 1990; 17:681-90
40. Prielipp RC, MacGregor DA, Butterworth JF, et al. Pharmacodynamics and pharmacokinetics of milrinone administration to increase oxygen delivery in critically ill patients. Chest 1996; 109:1291-1301
41. Barton P, Garcia J, kouatli A, et al. Hemodynamic effects of intravenous milrinone lactate in pediatric patients with septic shock. Chest 1996; 109:1302-12
42. McLean RF, Prielipp RC, Rosenthal MH. et al. Vasodilator therapy in microembolic porcine pulmonary hypertension. Anesth Analg; 1990; 71:35-41
43. Ghignonc M, Girling L, Prewitt RM. Effects of vasodilators on canine cardiopulmonary function when a decrease in cardiac output complicates an increase in right ventricular afterload. Am Rev Respir Dis 1985; 131:527-30
44. Lee KY, Molloy DW, Slykerman L, et al. Effects of hydralaziue and nitroprusside on cardiopulmonary function when a decrease in cardiac output complicates a short-term increase in pulmonary vascular resistance. Circulation 1983; 68:1299-1303
45. Bates ER, Crevey BJ, Sprague FR, et al. Oral hydralayine therapy for acute pulmonary embolism and low output state. Arch Intern Med 1981; 141:1537-38
46. Bottiger BW, Motsch J. Dorsam J, et al. Inhaled nitric oxide selectively decreases pulmonary artery pressure and pulmonary vascular resistance following acute massive pulmonary microembolism in piglets. Chest 1996; 110:1041-47
47. Prewitt RM. Hemodynamic management in pulmonary embolism and acute hypoxie respiratory failure. Crit Care Med 1990; 18:S61-69
48. Tapson VF, Witty LA. Massive Pulmonary embolism: diagnostic and therapeutic strategies. Clin Chest Med 1995; 16:329-40
49. Witty LA, Tapson VF, Wellendorf J, et al. Massive pulmonary embolism: local thrombolytic therapy with inotropic support [abstract|. Am J Respir Crit Care Med 1994; 149:A1064
50. Greenfield LJ. Catheter pulmonary embolectomy. Chest 1991; 100:593-94
51. Gray HH, Morgan JM, Paneth M, et al. Pulmonary embolectomy for acute massive pulmonary embolism: an analysis of 71 cases. Br Heart J 1988; 60:196-200
52. Tapson VF, Gurbel PA, Witty LA, et al. Pharmacomechanical thrombolysis of experimental pulmonary emboli: rapid lowdose intraembolic therapy. Chest 1994; 106:1558-62
53. Letsou GV, Franco KL, Detmer W. et al. Pulmonary artery balloon counterpulsation: safe after peripheral placement. Ann Thorac Surg 1993; 55:741-46
54. Sweet JM, Salerno PR, Panos A, et al. Feasibility of pulmonary artery balloon counterpulsation via the percutancous route: pathological studies on the heart and lungs. Can J Cardiol 1989; 5:352-56
55. Graham R, Skoog C, Macedo W, et al. Dopamine, dobutamine and phentolamine effects on pulmonary vascular mechanics. J Appl Physiol 1983; 54:1277-83